Why Delta Air Lines, AbbVie, and SanDisk Shocked Shareholders This Week

On Friday, the S&P 500 (SNPINDEX: ^GSPC  ) fell almost 1%, bringing its total drop for the week to more than 2.5% and raising calls of a potential correction. Yet amid the near panic that investors saw at certain points during the week, some of the stocks that ended up in the losing column this week were surprising. Let's look at Delta Air Lines (NYSE: DAL  ) , AbbVie (NYSE: ABBV  ) , and SanDisk (NASDAQ: SNDK  ) to see what they lost so much ground this week and whether it's justified.

Delta Air Lines fell 6% this week, as investors prepare for what's likely to be a poor winter quarter because of weather problems. But Delta has a long history of outperformance during the current market cycle, with the airline having much more flexibility than its rivals in how to deploy its ample free cash flow toward bettering its business or rewarding shareholders. With its role in pioneering ancillary charges like baggage fees while also keeping capital expenditures down, Delta Air Lines could keep soaring far into the future even when the airline industry doesn't enjoy as many advantages as it does right now.

AbbVie dropped more than 10% in the general exodus from health-care and biotech stocks. But the thing to remember about AbbVie is that it hasn't soared nearly as much as higher-profile biotech growth giants, largely due to uncertainties about how AbbVie will transition away from its heavy reliance on sales of blockbuster drug Humira when it loses patent protection. Still, AbbVie actually had good news this week, with positive late-stage study results having competitive implications in the hot hepatitis C treatment market. With Humira going off-patent in 2016, AbbVie needs to act fast, but it has the ability to find winning therapies and bounce back from its patent-cliff issues.

Source: SanDisk.

SanDisk declined 9%. Investors got nervous about memory-chip makers this week, as the group had enjoyed some powerful gains over the past year and looked poised for a pullback. But SanDisk is in a powerful position in the industry, with its flash memory helping to power electronic devices of all kinds, ranging from smartphones and tablets to portable cameras and camcorders. More importantly, SanDisk has made an impressive foray into solid-state drives, both in high-end drives with pure solid-state memory as well as through partnerships with one hard-disk drive giant to produce solid-state hybrid drives that bridge the price and performance gap between old-style hard-disk drives and more expensive pure solid-state drives. Even if margins for memory decline, SanDisk has room to enjoy long-term growth as emerging markets catch up to developed markets and their hunger for faster storage.

Just because stocks drop doesn't mean that they're bad investments. In fact, many times, a drop is exactly what you need to give you the right risk-reward trade-off to buy a stock.

R.I.P. Internet -- 1969-2014
At only 45 years old, the Internet will be laid to rest in 2014. And Silicon Valley is thrilled. The Economist believes the death of the Internet "will be transformative." In fact, the CEO of one of the largest tech companies on the planet says somebody's going to bank "$14.4 trillion in profit from one concept alone."

Click here for a free video that gives you what you need to capitalize on the little-known company behind this concept.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 14, 2014, at 10:17 AM, PEStudent wrote:

    "AbbVie is that it hasn't soared nearly as much as higher-profile biotech growth giants, largely due to uncertainties about how AbbVie will transition away from its heavy reliance on sales of blockbuster drug Humira when it loses patent protection."

    Two arguments against those points:

    I'd say Abbvie soared. We Abbott Lab stockholders got one share of the new-spinoff Abbvie stock for each share of Abbott stock on the first trading day of 2013 for $35. It closed the year at $52.81 and is $47.26 now after more than a 10% drop.

    When Abbvie loses Humira patent protection in 2016 it will take some years to lose sales for two reasons:

    1) it's grown biologically through a DNA sequence that no one else has.

    2) the process isn't cheap to set up.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2913064, ~/Articles/ArticleHandler.aspx, 8/31/2015 12:55:52 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Dan Caplinger

Dan Caplinger has been a contract writer for the Motley Fool since 2006. As the Fool's Director of Investment Planning, Dan oversees much of the personal-finance and investment-planning content published daily on With a background as an estate-planning attorney and independent financial consultant, Dan's articles are based on more than 20 years of experience from all angles of the financial world.

Today's Market

updated 2 days ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 4:55 PM
^GSPC $1988.87 Up +1.21 +0.06%
S&P 500 INDEX CAPS Rating: No stars
ABBV $63.98 Down -0.53 -0.82%
AbbVie Inc. CAPS Rating: ****
DAL $43.94 Up +0.08 +0.18%
Delta Air Lines, I… CAPS Rating: ***
SNDK $52.27 Down -0.58 -1.10%
SanDisk Corp CAPS Rating: ****